PMID- 37581323
OWN - NLM
STAT- MEDLINE
DCOM- 20240130
LR  - 20240210
IS  - 1875-6190 (Electronic)
IS  - 1570-159X (Print)
IS  - 1570-159X (Linking)
VI  - 22
IP  - 5
DP  - 2024
TI  - The HPA Axis as Target for Depression.
PG  - 904-915
LID - 10.2174/1570159X21666230811141557 [doi]
AB  - Major depressive disorder (MDD) is a stress-related mental disorder with a 
      lifetime prevalence of 20% and, thus, is one of the most prevalent mental health 
      disorders worldwide. Many studies with a large number of patients support the 
      notion that abnormalities of the hypothalamus-pituitaryadrenal (HPA) axis are 
      crucial for the development of MDD. Therefore, a number of strategies and drugs 
      have been investigated to target different components of the HPA axis: 1) 
      corticotrophinreleasing hormone (CRH) 1 receptor antagonists; 2) vasopressin 
      V(1B) receptor antagonists, 3) glucocorticoid receptor antagonists, and 4) FKBP5 
      antagonists. Until now, V(1B) receptor antagonists and GR antagonists have 
      provided the most promising results. Preclinical data also support antagonists of 
      FKBP5, which seem to be partly responsible for the effects exerted by ketamine. 
      However, as HPA axis alterations occur only in a subset of patients, specific 
      treatment approaches that target only single components of the HPA axis will be 
      effective only in this subset of patients. Companion tests that measure the 
      function of the HPA axis and identify patients with an impaired HPA axis, such as 
      the dexamethasone-corticotrophin-releasing hormone (dex-CRH) test or the 
      molecular dexamethasonesuppression (mDST) test, may match the patient with an 
      effective treatment to enable patient-tailored treatments in terms of a precision 
      medicine approach.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Menke, Andreas
AU  - Menke A
AD  - Department of Psychosomatic Medicine and Psychotherapy, Medical Park 
      Chiemseeblick, Rasthausstr, 25, 83233 Bernau am Chiemsee, Germany.
AD  - Department of Psychiatry and Psychotherapy, University Hospital, Ludwig 
      Maximilian University of Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Neuropharmacol
JT  - Current neuropharmacology
JID - 101157239
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
SB  - IM
MH  - Humans
MH  - *Depressive Disorder, Major/drug therapy
MH  - Depression
MH  - Hypothalamo-Hypophyseal System/metabolism
MH  - Pituitary-Adrenal System/metabolism
MH  - Corticotropin-Releasing Hormone/metabolism/pharmacology/therapeutic use
PMC - PMC10845091
OTO - NOTNLM
OT  - CRH1
OT  - FKBP5
OT  - HPA axis
OT  - SSR149415
OT  - V1B receptor antagonist
OT  - antidepressants
OT  - biomarkers
OT  - depression
OT  - glucocorticoid receptor.
OT  - precision medicine
OT  - stress
OT  - vasopressin
COIS- The author acknowledges the health insurance company, AOK, the Bavarian General 
      Practitioner's Association, Medice and Neuraxpharm.
EDAT- 2023/08/15 12:42
MHDA- 2024/01/30 12:43
PMCR- 2024/07/04
CRDT- 2023/08/15 07:03
PHST- 2022/11/16 00:00 [received]
PHST- 2022/12/30 00:00 [revised]
PHST- 2023/01/04 00:00 [accepted]
PHST- 2024/07/04 00:00 [pmc-release]
PHST- 2024/01/30 12:43 [medline]
PHST- 2023/08/15 12:42 [pubmed]
PHST- 2023/08/15 07:03 [entrez]
AID - CN-EPUB-133562 [pii]
AID - CN-22-904 [pii]
AID - 10.2174/1570159X21666230811141557 [doi]
PST - ppublish
SO  - Curr Neuropharmacol. 2024;22(5):904-915. doi: 10.2174/1570159X21666230811141557.